SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-055588
Filing Date
2024-05-08
Accepted
2024-05-08 16:01:21
Documents
61
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ctmx-20240331.htm   iXBRL 10-Q 1872436
2 EX-10.1 ctmx-ex10_1.htm EX-10.1 44051
3 EX-31.1 ctmx-ex31_1.htm EX-31.1 16689
4 EX-31.2 ctmx-ex31_2.htm EX-31.2 16823
5 EX-32.1 ctmx-ex32_1.htm EX-32.1 11913
6 EX-32.2 ctmx-ex32_2.htm EX-32.2 11879
  Complete submission text file 0000950170-24-055588.txt   6932748

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ctmx-20240331.xsd EX-101.SCH 1136150
65 EXTRACTED XBRL INSTANCE DOCUMENT ctmx-20240331_htm.xml XML 903991
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37587 | Film No.: 24925724
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)